Log In
Print
BCIQ
Print
Print this Print this
 

JNJ-26854165

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionHuman MDM2 antagonist
Molecular Target Mdm2 p53 binding protein homolog (MDM2) (HDM2)
Mechanism of ActionMdm2 p53 binding protein homolog (MDM2) antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced, refractory solid tumors
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today